{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T19:16:16Z","timestamp":1770318976896,"version":"3.49.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fondaparinux sodium, a synthetic pentose sugar, selectively inhibits factor Xa and is mainly used to prevent venous thromboembolism during major lower extremity orthopedic surgeries. It is also utilized for treating unstable angina pectoris and non-ST-segment-elevation myocardial infarction (NSTEMI). Given its extensive clinical application, comprehensive evaluation of its safety profile in clinical practice is essential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This pharmacovigilance investigation systematically evaluated the post-marketing safety profile of fondaparinux sodium by leveraging real-world data from the FDA Adverse Event Reporting System (FAERS) database (Q1 2004 to Q3 2024), where fondaparinux sodium was the primary suspected drug. To further validate the robustness and generalizability of our findings, we cross-referenced the identified signals with data from two external sources: the VigiAccess database (Q2 2003 to Q4 2025) and the Japanese Adverse Drug Event Report (JADER) database (Q2 2007 to Q2 2025). Disproportionality analyses employed the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multiple empirical Bayes Gamma\u2013Poisson shrinker (MGPS). Furthermore, sensitivity analyses were conducted to ensure the robustness of the results. Finally, the optimal parametric model was applied to estimate the temporal risk of adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the FAERS database, we identified 5,700 fondaparinux sodium-related AE reports, corresponding to 17,061 unique Preferred Terms (PTs). Time-to-onset analysis (\n                      <jats:italic>N<\/jats:italic>\n                      \u202f=\u202f2,220) showed an early-peak profile (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u202f=\u202f1.2, median: 7\u202fdays), with 81.98% of events within 30\u202fdays. Disproportionality analysis confirmed positive signals for haemorrhagic complications across all demographics. Subgroup analysis revealed higher bleeding RORs in females, and increased risks of anemia and skin necrosis in the elderly patients(\u2265 65\u202fyears). Pediatric patients (&amp;lt; 18\u202fyears) showed rare but significant hepatotoxicity. Healthcare professionals reported more complex clinical terms, while consumers reported more symptomatic events. Several unbalanced signals, including haematemesis (ROR\u202f=\u202f14.52, 95%CI: 11.99\u201317.58) and skin necrosis (ROR\u202f=\u202f27.29, 95%CI: 20.06\u201337.12) were identified. Sensitivity analyses further confirmed the robustness of these findings, and key signals were cross-referenced with the VigiAccess database and JADER database. The detection of these signals highlights potential safety concerns that warrant further clinical monitoring rather than confirming definitive causality.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study serves as a hypothesis-generating inquiry into the real-world safety of fondaparinux sodium. While our findings align with established adverse reaction profiles, they also highlight potential novel signals that warrant further investigation. These insights provide valuable reference points for clinical monitoring, particularly in special populations, though further epidemiological studies are needed to verify causality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1731378","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:44:54Z","timestamp":1770273894000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse event profile of fondaparinux sodium: a disproportionality analysis based on FAERS, JADER, and VigiAccess databases"],"prefix":"10.3389","volume":"13","author":[{"given":"Wei","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianwei","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menglu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University","place":["Yiwu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.thromres.2015.04.001","article-title":"Fondaparinux in pregnancy: could it be a safe option? A review of the literature","volume":"135","author":"De Carolis","year":"2015","journal-title":"Thromb Res"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"10742484221145010","DOI":"10.1177\/10742484221145010","article-title":"Fondaparinux sodium: recent advances in the management of thrombosis","volume":"28","author":"Bauersachs","year":"2023","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejogrb.2023.05.031","article-title":"Pregnancy outcomes and adverse events in patients with recurrent miscarriage receiving fondaparinux versus low molecular-weight heparin: a meta-analysis","volume":"287","author":"Mu","year":"2023","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1620\/tjem.2023.j098","article-title":"Fondaparinux results in similar pregnancy outcomes with lower adverse reaction rates compared to low molecular weight heparin in Chinese recurrent miscarriage women","volume":"262","author":"Liu","year":"2024","journal-title":"Tohoku J Exp Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00228-025-03804-y","article-title":"Safety profiles of fondaparinux in pregnant women: a systematic review and meta-analysis","volume":"81","author":"Shan","year":"2025","journal-title":"Eur J Clin Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003088-200241002-00001","article-title":"The pharmacokinetics of fondaparinux sodium in healthy volunteers","author":"Donat","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1080\/14740338.2016.1221395","article-title":"The safety of fondaparinux sodium for the treatment of venous thromboembolism","volume":"15","author":"Mastroiacovo","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/FJC.0000000000001596","article-title":"Fondaparinux sodium for anticoagulant therapy after primary percutaneous coronary intervention: a single-center randomized trial in China","volume":"84","author":"Li","year":"2024","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"717630","DOI":"10.3389\/fendo.2021.717630","article-title":"Retrospective analysis of fondaparinux and low-molecular-weight heparin in the treatment of women with recurrent spontaneous abortion","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.thromres.2011.10.037","article-title":"Fondaparinux - data on efficacy and safety in special situations","volume":"129","author":"Nagler","year":"2012","journal-title":"Thromb Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1352982","DOI":"10.3389\/fphar.2024.1352982","article-title":"Unlocking the potential of fondaparinux: guideline for optimal usage and clinical suggestions (2023)","volume":"15","author":"Yin","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/cpt.3139","article-title":"Drug-induced acute pancreatitis: a real-world pharmacovigilance study using the FDA adverse event reporting system database","volume":"115","author":"Li","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/14740338.2024.2355336","article-title":"Abrocitinib-associated adverse events: a real-world pharmacovigilance study using the FAERS database","volume":"24","author":"Sun","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"ref14","doi-asserted-by":"crossref","DOI":"10.1201\/9781032629940","volume-title":"Signal analysis in pharmacovigilance: principles and processes","author":"Kumar","year":"2024"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.1097\/JS9.0000000000002592","article-title":"Unveiling the hidden risks: analysis of adverse drug reactions associated with probiotics from the FAERS database - quality improvement study","volume":"111","author":"Jiao","year":"2025","journal-title":"Int J Surg"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"8148","DOI":"10.1038\/s41598-025-92605-5","article-title":"Adverse events reporting of edaravone: a real-world analysis from FAERS database","volume":"15","author":"Shang","year":"2025","journal-title":"Sci Rep"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1333662","DOI":"10.3389\/fphar.2024.1333662","article-title":"A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf J"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ajo.2025.05.007","article-title":"Association of Glucagon-like Peptide-1 receptor agonists with optic nerve and retinal adverse events: a population-based observational study across 180 countries","volume":"277","author":"Lakhani","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2147\/CLEP.S470959","article-title":"Drug-induced gynecomastia: data mining and analysis of the FDA adverse event reporting system database","volume":"16","author":"Yang","year":"2024","journal-title":"Clin Epidemiol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The reporting of a disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s40264-023-01334-z","article-title":"Disproportionality analysis of Abemaciclib in the FDA adverse event reporting system: a real-world post-marketing pharmacovigilance assessment","volume":"46","author":"Shu","year":"2023","journal-title":"Drug Saf"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13098-024-01570-y","article-title":"Interaction between dipeptidyl-peptidase-4 inhibitors and drugs acting on renin angiotensin aldosterone system for the risk of angioedema: a pharmacovigilance assessment using disproportionality and interaction analyses","volume":"17","author":"Sridharan","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2025.2461200","article-title":"Mining and disproportionality analysis of adverse events signals for naltrexone based on real-world data from the FAERS database","author":"Zeng","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e70084","DOI":"10.1002\/pds.70084","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for obeticholic acid","volume":"34","author":"Hai","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA'S spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"31689","DOI":"10.1038\/s41598-025-17232-6","article-title":"A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system","volume":"15","author":"Chen","year":"2025","journal-title":"Sci Rep"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e0335449","DOI":"10.1371\/journal.pone.0335449","article-title":"Drug-induced movement disorder: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2004 to 2024","volume":"20","author":"Zou","year":"2025","journal-title":"PLoS One"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2165\/11532850-000000000-00000","article-title":"Modelling the time to onset of adverse reactions with parametric survival distributions: a potential approach to signal detection and evaluation","volume":"33","author":"Maignen","year":"2010","journal-title":"Drug Saf"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/S0149-2918(02)80077-7","article-title":"Fondaparinux: a new antithrombotic agent","volume":"24","author":"Cheng","year":"2002","journal-title":"Clin Ther"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e012184","DOI":"10.1161\/JAHA.119.012184","article-title":"Fondaparinux sodium compared with low-molecular-weight heparins for perioperative surgical Thromboprophylaxis: a systematic review and Meta-analysis","volume":"8","author":"Kumar","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"598","DOI":"10.12669\/pjms.37.2.3522","article-title":"Fondaparinux-associated thrombocytopenia","volume":"37","author":"Malik","year":"2021","journal-title":"Pak J Med Sci"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1056\/NEJMc070346","article-title":"Heparin-induced thrombocytopenia associated with fondaparinux","volume":"356","author":"Warkentin","year":"2007","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/MBC.0b013e328340ff24","article-title":"Fondaparinux cross-reacts with heparin antibodies in vitro in a patient with fondaparinux-related thrombocytopenia","volume":"22","author":"Pistulli","year":"2011","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1021\/acs.bioconjchem.2c00316","article-title":"When will fondaparinux induce thrombocytopenia?","volume":"33","author":"Chen","year":"2022","journal-title":"Bioconjug Chem"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct Oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"JAMA"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"17070","DOI":"10.1038\/s41598-025-01527-9","article-title":"Safety comparisons among different subcutaneous anticoagulants for venous thromboembolism using FDA adverse event reporting system","volume":"15","author":"Lu","year":"2025","journal-title":"Sci Rep"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"13955","DOI":"10.3390\/ijms232213955","article-title":"Gastrointestinal bleeding due to NOACs use: exploring the molecular mechanisms","volume":"23","author":"Saviano","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1136\/adc.2010.199919","article-title":"Purpura fulminans: recognition, diagnosis and management","volume":"96","author":"Chalmers","year":"2011","journal-title":"Arch Dis Child"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1182\/blood.v112.11.4062.4062","article-title":"Warfarin-induced skin necrosis in vasculitis","volume":"112","author":"Corinaldesi","year":"2008","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1517\/14740338.1.3.287","article-title":"Anticoagulant-related skin reactions","volume":"1","author":"J\u00f6rg","year":"2002","journal-title":"Expert Opin Drug Saf"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/mbc.0000000000001112","article-title":"A challenging case of heparin-induced skin necrosis without thrombocytopenia","volume":"33","author":"Chidharla","year":"2022","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1398-9995.2005.00695.x","article-title":"Unexpected delayed-type hypersensitivity skin reactions to the ultra-low-molecular-weight heparin fondaparinux","volume":"60","author":"Maetzke","year":"2005","journal-title":"Allergy"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"759","DOI":"10.7326\/0003-4819-79-5-759_1","article-title":"Letter: heparin: adverse reaction","volume":"79","author":"O'Toole","year":"1973","journal-title":"Ann Intern Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/10245332.1997.11746333","article-title":"Skin necrosis associated with heparin-induced thrombocytopenia and thrombosis","volume":"2","author":"Giles","year":"1997","journal-title":"Hematology"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1002\/ajh.21026","article-title":"Heparin-induced skin necrosis associated with thrombocytopenia and acquired protein C and protein S deficiency","volume":"82","author":"Prasad","year":"2007","journal-title":"Am J Hematol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1586\/ehm.10.54","article-title":"Fondaparinux: does it cause HIT? Can it treat HIT?","volume":"3","author":"Warkentin","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"e495S","DOI":"10.1378\/chest.11-2303","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"142","author":"Linkins","year":"2012","journal-title":"Chest"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1001\/jama.294.7.813","article-title":"Acute renal failure in critically ill patients: a multinational, multicenter study","volume":"294","author":"Uchino","year":"2005","journal-title":"JAMA"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00134-015-3934-7","article-title":"Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study","volume":"41","author":"Hoste","year":"2015","journal-title":"Intensive Care Med"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.2165\/00003495-200262110-00007","article-title":"Fondaparinux sodium","volume":"62","author":"Keam","year":"2002","journal-title":"Drugs"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1055\/s-0038-1649967","article-title":"Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107\/Org31540) with high affinity to antithrombin III in man","volume":"74","author":"Boneu","year":"1995","journal-title":"Thromb Haemost"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/MBC.0b013e328323da86","article-title":"Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients","volume":"20","author":"Turpie","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1007\/s11239-012-0773-z","article-title":"Plasma accumulation of fondaparinux 2.5 mg in patients after total hip arthroplasty","volume":"34","author":"Yukizawa","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"887020","DOI":"10.3389\/fphar.2022.887020","article-title":"Safety and effectiveness of fondaparinux as a postpartum thromboprophylaxis during puerperium among muslim women: a single Centre prospective study","volume":"13","author":"Muhamad","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jhep.2012.09.015","article-title":"Fondaparinux (Arixtra *) hepatotoxicity in a 6 year-old child","volume":"58","author":"Orostegui","year":"2013","journal-title":"J Hepatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1731378\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:44:55Z","timestamp":1770273895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1731378\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":61,"alternative-id":["10.3389\/fmed.2026.1731378"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1731378","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"article-number":"1731378"}}